Investigational Drug Information for Cebranopadol
✉ Email this page to a colleague
What is the development status for investigational drug Cebranopadol?
Cebranopadol is an investigational drug.
There have been 9 clinical trials for Cebranopadol.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 29th 2013.
The most common disease conditions in clinical trials are Chronic Pain, Peripheral Nervous System Diseases, and Diabetic Neuropathies. The leading clinical trial sponsors are Tris Pharma, Inc., Grünenthal GmbH, and Forest Laboratories.
Summary for Cebranopadol
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 191 |
| WIPO Patent Applications | 69 |
| Japanese Patent Applications | 13 |
| Clinical Trial Progress | Phase 3 (2013-10-29) |
| Vendors | 42 |
Recent Clinical Trials for Cebranopadol
| Title | Sponsor | Phase |
|---|---|---|
| Cebranopadol Effects on Ventilatory Drive, Central Nervous System (CNS) and Pain. | Tris Pharma, Inc. | Phase 1 |
| Assessment of Abuse Potential of Cebranopadol in Humans | Tris Pharma, Inc. | Phase 1 |
| CORAL XT - Open-label Extension Trial of the CORAL Trial | Grünenthal GmbH | Phase 3 |
Clinical Trial Summary for Cebranopadol
Top disease conditions for Cebranopadol
Top clinical trial sponsors for Cebranopadol
US Patents for Cebranopadol
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
